Dr. rer. nat. Alf Spitschak

Dr. rer. nat.  Alf Spitschak

Tel.: (+49) 381 494-4958
Fax.: (+49) 381 494-5062



    Theranostics. 2019 Feb 20;9(5):1490-1509. doi: 10.7150/thno.29546.
    Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers.
    Goody D, Gupta SK, Engelmann D, Spitschak A, Marquardt S, Mikkat S, Meier C, Hauser C, Gundlach JP, Egberts JH, Martin H, Schumacher T, Trauzold A, Wolkenhauer O, Logotheti S, Pützer BM.
    Cancer Lett. 2018 Nov 13. pii: S0304-3835(18)30673-6. doi: 10.1016/j.canlet.2018.11.009.
    DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression.
    Fürst K, Steder M, Logotheti S, Angerilli A, Spitschak A, Marquardt S, Schumacher T, Engelmann D, Herchenröder O, Rupp RAW, Pützer BM.
    Semin Cancer Biol. 2018 Jun 29. pii: S1044-579X(18)30018-X. doi: 10.1016/j.
    Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
    Marquardt S, Solanki M, Spitschak A, Vera J, Pützer BM.
    Theranostics 2018; 8(4):1106-1120.
    MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance.
    Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, Wolkenhauer O, Pützer BM, Vera J.
    Nat Commun. 2017 Aug 4;8(1):198.
    Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures.
    Khan FM, Marquardt S, Gupta SK, Knoll S, Schmitz U, Spitschak A, Engelmann D, Vera J, Wolkenhauer O, Pützer BM.
    Mol Cancer. 2017 Jan 26;16(1):24.
    MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A, Meier C, Kowtharapu B, Engelmann D, Pützer BM
    J Urol. 2016 Aug;196(2):570-8.
    Integrated loss of miR-1/-101/-204 discriminates metastatic from non-metastatic penile carcinomas and can predict patient outcome.
    Hartz JM, Engelmann D, Fürst K, Marquardt S, Spitschak A, Goody D, Protzel C, Hakenberg OW, Pützer BM.
    Nucleic Acids Res. 2016 Jan 8;44(1):117-33.
    Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.
    Wang Y, Alla V, Goody D, Gupta SK, Spitschak A, Wolkenhauer O, Pützer BM, Engelmann D.
    Int J Cancer. 2016 Apr 1;138(7):1792-801.
    Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, Hilgendorf I, Hirt C, Ho AD, Freund M, Schmitt M.
    J Pathol. 2014 Nov;234(3):351-64.
    Association of RHAMM with E2F1 promotes tumor cell extravasation by transcriptional upregulation of fibronectin.
    Meier C, Spitschak A, Abshagen K, Gupta S, Mor JM, Wolkenhauer O, Haier J, Vollmar B, Alla V, Pützer BM.
    Cancer Cell, Volume 24, Issue 4, 512-527, 14 October 2013
    DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT/STAT3 Signaling
    Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Fürst K, Kowtharapu BS, Engelmann D, Petigk J, Egberts F, Schäd-Trcka SG, Gross G, Nettelbeck DM, Niemetz A, Pützer BM.
    J Mol Cell Biol. 2013 Dec;5(6):391-403.
    E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.
    Engelmann D, Mayoli-Nüssle D, Mayrhofer C, Fürst K, Alla V, Stoll A, Spitschak A, Abshagen K, Vollmar B, Ran S, Pützer BM.
    Clin Dev Immunol. 2012;2012:146463. doi: 10.1155/2012/146463. Epub 2012 Jun 6.
    Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R, Meier C, Schmitt A, Spitschak A, Hilgendorf I, Rohde S, Hirt C, Freund M, Pützer BM, Schmitt M.
    Clin Endocrinol (Oxf). 2011 Jun 28.
    Germline RET Sequence Variation I852M and Occult Medullary Thyroid Cancer: Harmless Polymorphism or Causative Mutation?
    Machens A, Spitschak A, Lorenz K, Pützer BM, Dralle H.